Recent Developments in Digital Therapeutics (DTx) Market

• Welldoc(US) partnered with Dexacom (US). This partnership helped provide BlueStar with Dexcom G6 CGM as a single platform to people with Type 2 diabetes for improved health.
• Pear Therapeutics (US) partnered with Sprectrum Health Systems (US). Tufts Health Plan and Spectrum Health Systems announced a collaboration with Pear Therapeutics to test FDA-approved digital therapeutics to help people with substance use disorders and improve their recovery journeys by delivering solutions for improved treatment access and care innovation journeys by delivering solutions for improved treatment access and care innovation

According to a research report "Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global Forecasts to 2026", is projected to reach USD 13.1 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 31.4% during the forecast period.

Get Informational PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

The growth of this market is mainly driven by the increasing incidence of preventable chronic diseases, the need to manage healthcare costs, increasing interest in preventive healthcare, and increasing investments in digital therapies.

Prominent players in the digital therapeutics market include Omada Health (US), WellDoc (US), Pear Therapeutics (US), Better Therapeutics (US), Happify (US), Proteus Digital Health (US), Propeller Health (US), Noom (US), Livongo Health (US), Akili Interactive Labs (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), CogniFit (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), Wellthy Therapeutics (India), Cognoa (US), and Ginger (US).

Major Growth Boosting Factors:

Treatment/care-related applications form the largest segment of the market, by application.

The large share of this segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

The B2B segment is the largest and fastest-growing segment of the market during the forecast period.

This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

North America commanded the largest share of the digital therapeutics market

North America held the largest share of the market, followed by Europe. The market in North America is also expected to grow at the highest CAGR of 32.2%. Factors such as the influx of new start-ups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724